THERAPEUTIC DRUG-MONITORING IN ONCOLOGY - PROBLEMS AND POTENTIAL IN ANTINEOPLASTIC THERAPY

被引：60

作者：

MOORE, MJ ^{[1
]}

ERLICHMAN, C ^{[1
]}

机构：

[1] UNIV TORONTO, DEPT MED & PHARMACOL, TORONTO M5S 1A1, ONTARIO, CANADA

来源：

关键词：

D O I：

10.2165/00003088-198713040-00001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：205 / 227

页数：23

共 178 条

[1]

ALBERTS DS, 1979, CANCER CHEMOTH PHARM, V2, P127

[2]

ALBERTS DS, 1979, CLIN PHARMACOL THER, V26, P737

[3]

Ames M.M., 1983, PHARMACOKINETICS ANT

BALIS, FM .

[5]

BALIS FM, 1983, CANCER RES, V43, P2342

BELL, MR ;

MEREDITH, DJ ;

GILL, PG .

AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1985, 15 (02) :235-240

[7]

BENJAMIN RS, 1974, CANCER, V33, P19, DOI 10.1002/1097-0142(197401)33:1<19::AID-CNCR2820330107>3.0.CO

[8]

2-M

[9]

BENNETT WM, 1980, CANCER TREAT REP, V64, P921

[10] CYCLOSPORINE NEPHROTOXICITY [J].

BENNETT, WM ;

PULLIAM, JP .